• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上皮性卵巢癌中BRCA1的甲基化状态与免疫组织化学

Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer.

作者信息

Pradjatmo Heru, Dasuki Djaswadi, Anwar Mohammad, Mubarika Sofia

机构信息

Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia E-mail :

出版信息

Asian Pac J Cancer Prev. 2014;15(21):9479-85. doi: 10.7314/apjcp.2014.15.21.9479.

DOI:10.7314/apjcp.2014.15.21.9479
PMID:25422243
Abstract

BACKGROUND

Cancer initiation and progression are controlled by genetic and epigenetic events. One epigenetic process which is widely known is DNA methylation, a cause of gene silencing. If a gene is silenced the protein which it encodes will not expressed.

OBJECTIVES

  1. Identify the methylation status of BRCA1 in patients with epithelial ovarian cancer (EOC)and assess BRCA1 protein expression in tumor tissue. 2. Examine whether BRCA1 gene methylation and BRCA1 protein are associated with survival of epithelial ovarian cancer patients.

METHODS

The study design was a prospective-cohort study, conducted at Sardjito hospital, Yogyakarta, Indonesia.

RESULTS

A total of 69 cases were analyzed in this study. The data showed that the methylation status of BRCA1 in EOC was positive in 89.9%, with clear protein expression of BRCA1 in 31.9%. Methylation status and expression of BRCA1 were not prognosticators of EOC patients. Menarche, CA125 level, clinical stage and residual tumor were independent factors for prognosis.

摘要

背景

癌症的发生和发展受遗传和表观遗传事件控制。一种广为人知的表观遗传过程是DNA甲基化,它是基因沉默的一个原因。如果一个基因被沉默,它所编码的蛋白质将不会表达。

目的

  1. 确定上皮性卵巢癌(EOC)患者中BRCA1的甲基化状态,并评估肿瘤组织中BRCA1蛋白的表达。2. 研究BRCA1基因甲基化和BRCA1蛋白是否与上皮性卵巢癌患者的生存相关。

方法

本研究为前瞻性队列研究,在印度尼西亚日惹的萨迪托医院进行。

结果

本研究共分析了69例病例。数据显示,EOC中BRCA1的甲基化状态阳性率为89.9%,BRCA1蛋白清晰表达率为31.9%。BRCA1的甲基化状态和表达不是EOC患者的预后指标。初潮、CA125水平、临床分期和残留肿瘤是预后的独立因素。

相似文献

1
Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer.上皮性卵巢癌中BRCA1的甲基化状态与免疫组织化学
Asian Pac J Cancer Prev. 2014;15(21):9479-85. doi: 10.7314/apjcp.2014.15.21.9479.
2
Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.越南卵巢癌女性中BRCA1、RASSF1A和雌激素受体的甲基化谱
Asian Pac J Cancer Prev. 2013;14(12):7713-8. doi: 10.7314/apjcp.2013.14.12.7713.
3
Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.基因与表观遗传BRCA1沉默通路:对原发性卵巢癌患者的临床影响:肿瘤库卵巢癌联盟研究
Int J Gynecol Cancer. 2017 Oct;27(8):1658-1665. doi: 10.1097/IGC.0000000000001071.
4
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.BRCA1基因启动子高甲基化与卵巢癌蛋白表达——一项印度研究
Tumour Biol. 2014 May;35(5):4277-84. doi: 10.1007/s13277-013-1558-5. Epub 2014 Jan 3.
5
No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients.在接受铂类治疗的上皮性卵巢癌患者中,BRCA1免疫组化表达与肿瘤分级、分期或总生存期之间无关联。
Asian Pac J Cancer Prev. 2014;15(10):4275-9. doi: 10.7314/apjcp.2014.15.10.4275.
6
The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.BRCA状态在上皮性卵巢癌患者预后中的作用:一项文献系统评价及荟萃分析
PLoS One. 2014 May 1;9(5):e95285. doi: 10.1371/journal.pone.0095285. eCollection 2014.
7
DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.DNA低甲基化介导的癌症/睾丸抗原45(CT45)基因激活与上皮性卵巢癌的疾病进展和生存期缩短相关。
Epigenetics. 2015;10(8):736-48. doi: 10.1080/15592294.2015.1062206.
8
BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.BRCA1 启动子甲基化是散发性上皮性卵巢癌对铂类-紫杉烷类为基础的治疗反应更好的标志物。
J Cancer Res Clin Oncol. 2014 Sep;140(9):1457-63. doi: 10.1007/s00432-014-1704-5. Epub 2014 May 14.
9
Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.FANCF启动子高甲基化与上皮性卵巢癌的易感性及预后
Reprod Sci. 2016 Jan;23(1):24-30. doi: 10.1177/1933719115612136. Epub 2015 Oct 27.
10
BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.BRCA1/2 突变与表达:晚期上皮性卵巢癌患者铂类化疗的反应。
Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.

引用本文的文献

1
BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine.BRCA1和BRCA2甲基化作为癌症的预后和预测生物标志物:在精准医学时代液体活检中的应用
Clin Epigenetics. 2024 Dec 6;16(1):178. doi: 10.1186/s13148-024-01787-8.
2
Epigenetic editing of promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells.表观遗传编辑启动子增加卵巢癌细胞对顺铂和奥拉帕利的敏感性。
Epigenetics. 2024 Dec;19(1):2357518. doi: 10.1080/15592294.2024.2357518. Epub 2024 May 26.
3
BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
循环肿瘤 DNA 中 BRCA1 启动子的高甲基化与卵巢癌患者生存改善相关。
Mol Oncol. 2021 Dec;15(12):3615-3625. doi: 10.1002/1878-0261.13108. Epub 2021 Oct 12.
4
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.BRCA1 启动子甲基化与卵巢癌的临床结局:一项个体患者数据的荟萃分析。
J Natl Cancer Inst. 2020 Dec 14;112(12):1190-1203. doi: 10.1093/jnci/djaa070.
5
BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.BRCA1 免疫组化表达与卵巢癌预后的关系:系统评价和荟萃分析。
Target Oncol. 2020 Feb;15(1):37-46. doi: 10.1007/s11523-020-00697-y.
6
Loss of promotor hypermethylation in recurrent high-grade ovarian cancer.复发性高级别卵巢癌中启动子高甲基化的缺失。
Oncotarget. 2017 Sep 15;8(47):83063-83074. doi: 10.18632/oncotarget.20945. eCollection 2017 Oct 10.